Pasithea Therapeutics (KTTA) Prepaid Assets (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Prepaid Assets of $1.8 million for Q1 2026, up 125.46% sequentially from $811456.0 in Q4 2025, and up 194.51% YoY from $621208.0 in Q1 2025.
Pasithea Therapeutics (KTTA) Prepaid Assets (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Prepaid Assets for 7 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Prepaid Assets rose 194.51% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 194.51% YoY) and the FY2025 annual result came in at $811456.0, up 168.12% from the prior year.
- Prepaid Assets improved to $1.8 million in Q1 2026 per KTTA's latest filing, from $811456.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $1.8 million in Q1 2026 and troughed at $19665.0 in Q3 2025.
- A 5-year average of $525773.7 and a median of $452195.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets sank 87.7% in 2023, then jumped 493.61% in 2025.
- Over 5 years, Prepaid Assets stood at $262992.0 in 2022, then plunged by 60.19% to $104707.0 in 2023, then surged by 189.04% to $302641.0 in 2024, then soared by 168.12% to $811456.0 in 2025, then soared by 125.46% to $1.8 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.8 million, $811456.0, and $19665.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 811,456.00 |
| Sep 30, 2025 | 19,665.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 621,208.00 |
| Dec 31, 2024 | 302,641.00 |
| Sep 30, 2024 | 98,333.00 |
| Jun 30, 2024 | 570,242.00 |
| Mar 31, 2024 | 104,649.00 |
| Dec 31, 2023 | 104,707.00 |
| Sep 30, 2023 | 106,511.00 |
| Jun 30, 2023 | 452,195.00 |
| Mar 31, 2023 | 262,992.00 |
| Dec 31, 2022 | 262,992.00 |
| Sep 30, 2022 | 865,985.00 |
| Jun 30, 2022 | 594,613.00 |
| Mar 31, 2022 | 628,740.00 |
| Dec 31, 2021 | 333,751.00 |
| Sep 30, 2021 | 468,527.00 |
| Dec 31, 2020 | 4,308.00 |